-
AstraZeneca warns of potential tax fines amid China sales slowdown, illegal drug importation probe
06 Feb 2025 21:41 GMT
… -targeted antibody-drug conjugate from AstraZeneca and its partner Daiichi Sankyo. Last year …
-
Antibody Drug Conjugates (ADC) Market to Hit USD 29.10 Billion by 2032, Driven by Rising Cancer Cases
05 Feb 2025 13:53 GMT
… ability to deliver potent cytotoxic drugs directly to cancer cells, … Others
Key Players in Antibody Drug Conjugates Market
• Genentech (Herceptin … Adcetris, Tivdak)
• AstraZeneca (Enhertu, Lumoxiti)
• Daiichi Sankyo (Enhertu, DS-8201)
• Pfizer (Besponsa …
-
Daiichi Sankyo & AstraZeneca's datopotamab deruxtecan recommended for approval in EU to treat patients with previously treated metastatic HR positive, HER2 negative breast cancer
03 Feb 2025 10:20 GMT
… directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being … Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is … is being developed by Daiichi Sankyo.
The second Daiichi Sankyo ADC platform consists of …
-
B-Cell Non-Hodgkin Lymphoma FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights, Companies | DelveInsight
04 Feb 2025 12:31 GMT
… Cell Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and … Non-Hodgkin Lymphoma Emerging Drugs Profile
• Valemetostat: Daiichi Sankyo
Valemetostat is an … Phase II)
11. Valemetostat: Daiichi Sankyo
12. Drug profiles in the detailed report …
-
HER2 Positive Gastric Cancer FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies
04 Feb 2025 12:27 GMT
… landscape. It covers the pipeline drug profiles, including clinical and … Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc …
HER2 Positive Gastric Cancer Emerging Drugs Profile
• SHR-A1811: Jiangsu …
-
Daiichi Sankyo Appoints Chief Executive Officer
31 Jan 2025 20:07 GMT
… to the resurgence of antibody drug conjugate (ADC) development within the … to strengthen its management structure, Daiichi Sankyo’s Board of Directors appointed … resources during his tenure at Daiichi Sankyo. Mr. Okuzawa graduated from Hitotsubashi …
-
FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer
06 Feb 2025 20:35 GMT
… Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc … Enhertu will be posted on Drugs@FDA.
Efficacy and Safety
… Expedited Programs for Serious Conditions-Drugs and Biologics.
Healthcare professionals should …
-
Lipid Nanoparticle Raw Materials Market to Reach USD 378.13 Million by 2032, Driven by Advances in Drug Delivery
03 Feb 2025 12:39 GMT
… LNP formulations)
• Daiichi Sankyo - (Nanoparticle drug delivery, Innovative drug formulations)
• Celyad … biocompatibility, ability to carry drugs, and controlled release properties, … enhancing the need for drugs utilizing intestinal permeability as …
-
$89.5 Bn Anticoagulants Market Global Forecast 2025-2033 by Drug Class, Route of Administration, Distribution Channel, Application, Countries and Company Analysis - ResearchAndMarkets.com
03 Feb 2025 12:14 GMT
… Market Global Forecast Report by Drug Class, Route of Administration, … deaths.
Innovation in Anticoagulant Drugs
Newer drugs have been developed due … AG
Bristol-Myers Squibb Company
Daiichi Sankyo Company Limited
Dr. Reddy… 6.5 Country
7. Drug Class
7.1 Novel …
-
AstraZeneca and Daiichi’s breast cancer drug gets EU backing
31 Jan 2025 17:20 GMT
AstraZeneca and Daiichi Sankyo’s Datroway breast cancer treatment … pairs a tumor-killing drug with an antibody designed … some patients benefited from the drug, results across all patients … breast and lung cancers. The drug, previously called Dato-DXd, …
About
© 1995-2025